Specialists’ Individual Treatment Plans for Patients With FCS: PCP

Author(s):

Peter Toth, MD, PhD, FCCP, FESC, FAHA, FACC ,James Underberg, MS, MD, FACP, FACPM, FASPC, FASH, FNLA

Key Takeaways

Delayed FCS diagnosis can lead to exacerbated cardiovascular and metabolic consequences, increasing atherosclerosis and cardiovascular disease risk.
Persistent hypertriglyceridemia from untreated FCS may result in chronic pancreatitis, diabetes, and liver disease.
Early intervention is essential to manage triglyceride levels, prevent severe complications, and improve patient outcomes.

Panelists discuss their management approaches and unique considerations for patients with familial chylomicronemia syndrome (FCS) from the perspectives of endocrinologists, cardiologists, internists, and pancreatic specialists, highlighting specialized treatment strategies and collaborative care.

EP: 1.Overview of FCS

EP: 2.Severe Hypertriglyceridemia

EP: 3.Pathophysiology of FCS

EP: 4.Early Diagnosis

EP: 5.Genetic Testing

EP: 6.Metabolic Disorders and Delayed Diagnosis

EP: 7.FCS’ Affect on Quality of Life

EP: 8.Multidisciplinary Approach to Managing FCS

EP: 9.Medium Chain Fatty Acids

Now Viewing

EP: 10.Specialists’ Individual Treatment Plans for Patients With FCS: PCP

EP: 11.Specialists’ Individual Treatment Plans for Patients With FCS: Pancreatic Specialist

EP: 12.APOC3 Inhibitors

EP: 13.Current FCS Standard-of-Care Treatment Recommendations

EP: 14.FCS Patient Case study

EP: 15.Specialists’ Individual Treatment Plans for Patients With FCS patients: Pancreatic Specialist

EP: 16.The Current FCS Standard of Care Treatment Recommendations

Video content above is prompted by the following:

Please share your management approach and unique considerations for patients with FCS as a/an [endocrinologist / cardiologist / internist / pancreatic specialist]?